CHRS - Coherus BioSciences, Inc.
| Previous Close | 20.00 |
| Open | 20.10 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 19.81 - 20.84 |
| 52 Week Range | 8.32 - 23.43 |
| Volume | 708,872 |
| Avg. Volume | 1,053,087 |
| Market Cap | 1.435B |
| Beta (3Y Monthly) | 1.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.72 |
| Earnings Date | Nov 6, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.71 |
- Investor's Business Daily
Breakout Stocks & Technical Analysis
Get alerts to potential breakout stocks, along with technical analysis of the stock charts to see the best time to buy and what telltale signs to look for.
- Zacks
Investors Can Find Big Returns with this First Profit Screen
Investors Can Find Big Returns with this First Profit Screen
- Zacks
Coherus BioSciences (CHRS) Upgraded to Buy: Here's What You Should Know
Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Thomson Reuters StreetEvents
Edited Transcript of CHRS earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Coherus BioSciences Inc Earnings Call
- Investor's Business Daily
Stocks To Watch: Is Biosimilars Leader Coherus Biosciences Set To Rebound?
Boosted by rebounding earnings and sales growth and a promising pipeline, biosimilars leader Coherus Biosciences is approaching a potential new buy.
- GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Aug. 22, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective August 21, 2019, the compensation committee of the company’s.
- Simply Wall St.
Is Coherus BioSciences (NASDAQ:CHRS) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- GlobeNewswire
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in September
REDWOOD CITY, Calif., Aug. 21, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare.
Motley FoolCoherus BioSciences, Inc. (CHRS) Q2 2019 Earnings Call Transcript
CHRS earnings call for the period ending June 30, 2019.
- Zacks
Coherus BioSciences (CHRS) Beats Q2 Earnings and Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 500.00% and 2.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Coherus BioSciences Reports Corporate Highlights and Second Quarter 2019 Financial Results
– Company is Profitable and Cash flow Positive from Operations for Second Quarter – – UDENYCA® is the Market Leading Pegfilgrastim Biosimilar with Approximately 13% Market Share.
- GuruFocus.com
Steven Cohen Charges Into Chiasma
Guru invests in clinical-stage biopharmaceutical company Continue reading...
- GlobeNewswire
Coherus BioSciences Reports Victory in Pegfilgrastim Patent Dispute
REDWOOD CITY, Calif., July 29, 2019 -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that the United States Court of Appeals for the.
- Motley Fool
Why Deutsche Bank, Intra-Cellular Therapies, and Coherus BioSciences Slumped Today
Bad news on multiple fronts hit stocks.
- Motley Fool
Here's Why Coherus BioSciences Is Falling Today
The business reported an upbeat update, but something got lost in translation on Wall Street.
- Simply Wall St.
Are Investors Undervaluing Coherus BioSciences, Inc. (NASDAQ:CHRS) By 20%?
Today we will run through one way of estimating the intrinsic value of Coherus BioSciences, Inc. (NASDAQ:CHRS) by...
- GlobeNewswire
Coherus BioSciences Announces Unaudited Second Quarter 2019 UDENYCA® Net Sales of $79 Million to $84 Million
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Coherus’ expectations regarding the continued adoption of UDENYCA® in the U.S., estimation of channel mix, returns, chargebacks and rebates, each of which impact net sales computation. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made.
- GlobeNewswire
Coherus BioSciences to Report Second Quarter Financial Results on August 1st
REDWOOD CITY, Calif., July 08, 2019 -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its second quarter 2019 financial results will.
- GlobeNewswire
Coherus BioSciences Production Exceeds Four-Hundred Thousand UDENYCA® (pegfilgrastim-cbqv) Pre-Filled Syringes
Coherus BioSciences, Inc. (“Coherus” or “the Company,” Nasdaq: CHRS), is pleased to announce that it has produced over 400,000 UDENYCA® pre-filled syringes to date. The cumulative production of 400,000 UDENYCA® pre-filled syringes is a significant milestone, as it represents approximately one-third of the annual utilization of pegfilgrastim in the United States. “Coherus provides unencumbered choice of pegfilgrastim product to patients and providers in the United States," said Denny Lanfear, President and CEO of Coherus.
- Zacks
Coherus BioSciences (CHRS) Upgraded to Strong Buy: Here's Why
Coherus BioSciences (CHRS) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Coherus Biosciences Inc (CHRS)
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
- Markit
See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
Coherus BioSciences Inc NASDAQ NMS:CHRSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for CHRS with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on May 22. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding CHRS is favorable, with net inflows of $2.33 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
